Inhibikase Therapeutics Net Income 2011-2026 | IKT

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Inhibikase Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-48.3 M	-27.5 M	-19 M	-18.1 M	-14.8 M	-2.85 M	-5.72 M	-2.15 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-2.15 M	-48.3 M	-17.3 M

Quarterly Net Income Inhibikase Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-11.9 M	-9.92 M	-13.7 M	-	-5.78 M	-4.96 M	-4.65 M	-	-4.6 M	-5.78 M	-4.48 M	-	-4.49 M	-4.64 M	-4.64 M	-	-4.47 M	-2.64 M	-2.64 M	-	-671 K	-422 K	-547 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-422 K	-13.7 M	-5.05 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	-27 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	-19.2 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	67.3 M	-	2.54 %	$ 160 B	France
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Enlivex Therapeutics Ltd. ENLV	1.24 B	$ 0.81	-3.11 %	$ 37 M	Israel
Exelixis EXEL	783 M	$ 46.21	-5.11 %	$ 12.5 B	USA
Athira Pharma ATHA	-106 M	-	-	$ 269 M	USA
Fortress Biotech FBIO	6.82 M	$ 2.43	-4.71 %	$ 67.8 M	USA
Heron Therapeutics HRTX	-20.2 M	$ 1.24	-5.73 %	$ 207 M	USA
InflaRx N.V. IFRX	-45.6 M	$ 2.86	14.2 %	$ 192 M	Germany
Ionis Pharmaceuticals IONS	-229 M	$ 75.53	-1.72 %	$ 12.1 B	USA
BioNTech SE BNTX	10.3 B	$ 92.4	-3.0 %	$ 27.2 B	Germany
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Kymera Therapeutics KYMR	-311 M	$ 85.56	-0.81 %	$ 7.23 B	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Ligand Pharmaceuticals Incorporated LGND	-4.03 M	$ 212.11	-8.79 %	$ 3.88 B	USA
ACADIA Pharmaceuticals ACAD	226 M	$ 22.02	2.51 %	$ 3.65 B	USA
Mirum Pharmaceuticals MIRM	-23.4 M	$ 100.27	-8.92 %	$ 5.03 B	USA
MannKind Corporation MNKD	5.86 M	$ 3.59	0.7 %	$ 1.1 B	USA
Advaxis ADXS	-48.1 M	-	-9.65 %	$ 45.9 M	USA
Esperion Therapeutics ESPR	-22.7 M	$ 3.15	-	$ 655 M	USA
Can-Fite BioPharma Ltd. CANF	-9.83 M	$ 3.65	8.96 %	$ 6.01 M	Israel
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
Genprex GNPX	-16.2 M	$ 0.88	-1.48 %	$ 821 K	USA
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
Matinas BioPharma Holdings MTNB	-10.3 M	$ 0.65	-4.03 %	$ 3.56 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-22.4 M	-	1.93 %	$ 17.4 M	USA
Nanobiotix S.A. NBTX	-47 M	$ 43.46	3.82 %	$ 286 B	France
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	-25.5 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-64.8 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-86.7 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-34 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	-186 M	-	-	$ 28.6 M	USA
AlloVir ALVR	-43.4 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	-16.1 M	$ 21.33	-11.75 %	$ 2.71 B	USA
Allena Pharmaceuticals ALNA	-48.7 M	-	3.16 %	$ 1.9 M	USA
Genmab A/S GMAB	4.76 B	$ 27.16	-2.62 %	$ 16.8 B	Danmark
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-126 M	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	-57.8 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-49.9 M	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	-120 M	-	-	$ 8.42 M	USA